Targeting an energy sensor to prevent energy excess in the liver

Grace Lai-Hung Wong¹, Vincent Wai-Sun Wong²

Affiliations

¹ Medical Data Analytics Centre, Department of Medicine and Therapeutics, Institute of Digestive Disease, and State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.
² Medical Data Analytics Centre, Department of Medicine and Therapeutics, Institute of Digestive Disease, and State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China. Electronic address: wongv@cuhk.edu.hk.

PMID: 34560016
DOI: 10.1016/S2468-1253(21)00307-1

Comment

Targeting an energy sensor to prevent energy excess in the liver

Grace Lai-Hung Wong et al. Lancet Gastroenterol Hepatol. 2021 Nov.

. 2021 Nov;6(11):876-877.

doi: 10.1016/S2468-1253(21)00307-1. Epub 2021 Sep 22.

Authors

Grace Lai-Hung Wong¹, Vincent Wai-Sun Wong²

Affiliations

¹ Medical Data Analytics Centre, Department of Medicine and Therapeutics, Institute of Digestive Disease, and State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.
² Medical Data Analytics Centre, Department of Medicine and Therapeutics, Institute of Digestive Disease, and State Key Laboratory of Digestive Disease, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China. Electronic address: wongv@cuhk.edu.hk.

PMID: 34560016
DOI: 10.1016/S2468-1253(21)00307-1

No abstract available

PubMed Disclaimer

Conflict of interest statement

GL-HW has served as an advisory committee member for Gilead Sciences, and as a speaker for Abbott, AbbVie, Bristol Myers Squibb, Echosens, Furui, Gilead Sciences, Janssen, and Roche. VW-SW has served as an advisory committee member for AbbVie, Allergan, Echosens, Gilead Sciences, Janssen, Perspectum Diagnostics, Pfizer, and Terns, and a speaker for Bristol Myers Squibb, Echosens, Gilead Sciences, and Merck.

Comment on

Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study.
Cusi K, Alkhouri N, Harrison SA, Fouqueray P, Moller DE, Hallakou-Bozec S, Bolze S, Grouin JM, Jeannin Megnien S, Dubourg J, Ratziu V. Cusi K, et al. Lancet Gastroenterol Hepatol. 2021 Nov;6(11):889-902. doi: 10.1016/S2468-1253(21)00300-9. Epub 2021 Sep 22. Lancet Gastroenterol Hepatol. 2021. PMID: 34560015 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Targeting an energy sensor to prevent energy excess in the liver

Affiliations

Targeting an energy sensor to prevent energy excess in the liver

Authors

Affiliations

Conflict of interest statement

Comment on

Similar articles

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources